2 completed, 2 terminated, 1 recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow taladegib: new trials by email Literature Review of taladegib trials Research Report on taladegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants taladegib, nintedanib, pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 1 | Recruiting | Endeavor Biomedicines, Inc. | 57 | 2026-04-28 | 2026-05-15 |
| A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects taladegib, nintedanib - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Endeavor Biomedicines, Inc. | 21 | 2023-05-03 | 2023-12-15 |
| Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer Carboplatin, External Beam Radiation Therapy, Laboratory Biomarker Analysis - Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7 | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2017-03-07 | 2023-07-10 |
| A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors LY3039478, Taladegib, Abemaciclib - Solid Tumor, Breast Cancer | Phase 1 | Terminated | Eli Lilly and Company | 94 | 2016-11-04 | 2025-08-21 |
| A Study in Advanced Cancer Taladegib - Advanced Cancer | Phase 1 | Completed | Eli Lilly and Company | 84 | 2010-09-01 | 2019-09-13 |
Idiopathic Pulmonary Fibrosis (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pulmonary Fibrosis (1) · Sarcoma (1)
Eli Lilly and Company (2) · Endeavor Biomedicines, Inc. (2) · M.D. Anderson Cancer Center (1)
United States (3) · Australia (2) · Denmark (1) · France (1) · Spain (1)
Jaffer A Ajani (1) · Lisa Lancaster, M.D. (1) · Paul Frohna, M.D., Ph.D. (1)
2015 (1)